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Background Medium chain acyl-CoA dehydrogenase deficiency (MCADD) is a rare, life-
threatening condition. Early diagnosis by screening asymptomatic newborns may improve outcome,
but the benefit to newborns identified with variants not encountered clinically is uncertain.
Objective To estimate, overall and by ethnic group: screen-positive prevalence and predictive value
(PPV); MCADD prevalence; proportion MCADD variants detected of predicted definite or uncertain
clinical importance.
Setting All births in areas of high ethnic minority prevalence in England.
Methods Prospective multicentre pilot screening service; testing at age five to eight days;
standardized screening, diagnostic and management protocols; independent expert review of
screen-positive cases to assign MCADD diagnosis and predicted clinical importance (definite or
uncertain).
Results Approximately 1.5 million babies (79% white; 10% Asian) were screened. MCADD was
confirmed in 147 of 190 babies with a positive screening result (screen-positive prevalence: 1.20
per 10,000; MCADD prevalence: 0.94 per 10,000; PPV 77% [95% CI 71–83]), comprising 103
(70%) with MCADD variants of definite clinical importance (95 white [95%]; 2 Asian [2%]) and
44 (30%) with variants of uncertain clinical importance (29 white [67%]; 12 Asian [28%]).
Conclusion One baby in every 10,000 born in England is diagnosed with MCADD by newborn
screening; around 60 babies each year. While the majority of MCADD variants detected are
predicted to be of definite clinical importance, this varies according to ethnic group, with variants
of uncertain importance most commonly found in Asian babies. These findings provide support for
MCADD screening but highlight the need to take account of the ethnic diversity of the population
tested at implementation.
INTRODUCTION
M
edium chain acyl-CoA dehydrogenase deficiency
(MCADD) is an autosomal recessive disorder of
fatty acid oxidation, affecting between 1 in 10,000
to 27,000 babies of northern European descent.1 –5
MCADD results in reduced ability to break down fatty
acids to meet demands during periods of metabolic stress.
Typically, it presents during an intercurrent illness or a
period of fasting, with symptoms which can include hypo-
glycaemia, vomiting and encephalopathy. These may lead
to coma and sudden death which can be the presenting
feature in a child hitherto thought to be healthy. It has
been estimated that up to a quarter of previously undiag-
nosed children die during their initial acute episode, with
a further 16% surviving with a severe neurological
disability.6 –10 Once a diagnosis is made, a high carbohydrate
intake is given when at risk, together with avoidance of
fasting.11
Newborn screening for MCADD measured by tandem
mass spectrometry (MS/MS) based on the primary bio-
marker of octanoylcarnitine (C8)1 has been introduced in
many countries.12 –14 The short-term clinical outcome fol-
lowing presymptomatic diagnosis through screening is
good,15,16 although death and serious decompensation
may still occur.17,18 However, there is uncertainty as to
whether all those detected benefit from screening since
homozygosity for c.985A.G – the MCADD genotype most
associated with clinically severe disease – is found less
often in those detected through newborn screening com-
pared with those presenting clinically (55% and 80% of
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cases respectively)2,5,19– 27 and a two- to threefold increase
in MCADD diagnoses is reported.14,28,29 It is unclear to
what extent this difference reflects under-diagnosis of clini-
cally presenting children, reduced penetrance and the detec-
tion by newborn screening of a less severe disease that may
never present clinically.3,21,28,30 Many screen-detected
MCADD-associated genotypes have never been found
amongst reported symptomatic children.2 Furthermore,
England and Wales has a diverse ethnic population: over
20% of babies born are from a non-white ethnic origin,
with about half being of Asian (Indian subcontinent) ethni-
city,31,32 where little is known about the spectrum of geno-
type and any associated disease risk.
It was these considerations, coupled with a lack of high-
quality evidence regarding test performance, sample
timing, screening cut-off for C8, and the spectrum of
mutations in a UK context33,34 that led the UK
Department of Health and National Screening Committee
to commission a pilot screening service and a concurrent
research evaluation. We established a collaborative group
which designed a large-scale pilot MCADD screening
service, and undertook a prospective evaluation of screening
test performance and outcome using standardized, quality
assured screening and diagnostic protocols and with sys-
tematic ascertainment of all new diagnoses.
This pilot screening service was introduced in England in
March 2004 and ran for four years. We report here the per-
formance of this service, notably screen-positive prevalence
and predictive value (PPV), MCADD prevalence and the pro-
portion those diagnosed with MCADD in whom variants are
classified as definite or uncertain clinical importance.
METHODS
Study population
Babies were screened at five to eight days of age35 in areas
served by six newborn screening laboratories located in
areas of high minority ethnic prevalence.31 Together they
provide screening services to approximately 400,000
newborn infants each year, representing 60% of all births
in England and Wales.32 These six laboratories use electro-
spray tandem mass spectrometry (MS/MS) to screen for
phenylketonuria and have access to specialist clinical meta-
bolic services. Standardized protocols were developed
together with proformas for the prospective reporting of
data. Screening for MCADD was not offered in other
English laboratories during the pilot phase.
Screening protocol
Following midwife gained consent, a heel prick blood
sample was collected onto Whatman or Schleicher and
Schuell 903 (ID Biological Systems) filter paper cards as
four dried blood spots (DBS). Laboratories analysed a
single 3 mm punch without derivitization using MS/MS
with multiple reaction mode (MRM) acquisitions for quanti-
tation of octanoylcarnitine (C8), measured using an agreed
single common screening protocol (Figure 1) with values
0.40 mmol/L repeated in duplicate using the same DBS
sample. A presumptive positive screening result for
MCADD was defined as an average triplicate C8 value
0.50 mmol/L. A full acylcarnitine profile was performed
on presumptive positive samples.
Diagnostic and clinical management protocols
All presumptive positive babies were referred for further
diagnostic testing. Laboratory or clinical liaison staff con-
tacted an assigned specialist paediatric metabolic team to
arrange an emergency appointment for the family within
24 hours of the reported screening result. The family and
their general practitioner (GP or family doctor) were con-
tacted on the same day with the screening test result, infor-
mation about MCADD, emergency contact numbers and the
appointment details.
Results of the full acylcarnitine profile from the screening
sample were available at the first appointment. Clinicians
followed an agreed diagnostic testing protocol and clinical
management schedule as detailed in Figure 2. Initial diag-
nostic test results were available for parents within one
week. Extended mutation screening (EMS) was arranged
for all babies not homozygous for c.985A . G when
associated with a persistent biochemical abnormality,
defined as an average repeat C8  0.50 mmol/L and/or
abnormal qualitative urine organic acid (UOA) profile and/
or quantitative urine organic acid (hexanoylglycine)
1.1 mmol/mmol creatinine.36 DNA was extracted from
blood samples and PCR amplifications of all exons, including
part of the flanking intron sequences of the human
MCAD gene (ACADM) were carried out using intron-located
primers under standard conditions. PCR fragments
were sequenced on a 3100-Avant genetic analyzer using
BigDyew Terminator v1.1 Cycle Sequencing kit
(Applied Biosystems). We estimate that this strategy detects
at least .95% of the causative mutations, since only two
deletions have been described in the MCAD gene37,38 and
several studies have demonstrated that gross genomic
rearrangements in ACADM are very rare indeed.3,39 –43
Figure 1 Screening protocol
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Fibroblast fatty acid oxidation (FAO) studies44 were rec-
ommended if mutations were identified of uncertain clinical
significance.
Diagnostic and clinical management schedules for ‘at risk’
siblings included C8, qualitative UOA tests and genotyping
once the proband diagnosis was confirmed.
External Quality Assurance (EQA)
An EQA scheme was established, based at Birmingham
Children’s Hospital, providing a quality assessment of pre-
cision and accuracy for the analysis of C8 by MS/MS.45
Monthly specimens were circulated and results were ana-
lysed and reported back to all participating laboratories.
Furthermore, a (quarterly) molecular EQA scheme was
established for c.985A.G testing and monthly statistical
summaries of population C8 values were produced to
monitor between and within laboratory variation in popu-
lation distributions.46
Data notification and analysis
All presumptive positive screened babies were notified
directly to the study co-ordinating centre by laboratory
staff using an agreed standard proforma. Concurrently,
paediatricians notified all newly diagnosed children with
MCADD, including any diagnoses or deaths prior to screen-
ing, through the British Paediatric Surveillance Unit
(BPSU).47 Notifications were followed up with question-
naires which were returned to the study co-ordinating
centre. Data collected included initials, date of birth, partial
postcode (for de-duplication), sex and ethnicity in addition
to full screening and diagnostic test results and dates. Data
were stored on a relational database (Microsoft Access
2003) and analysed using Stata IC version 10
(StataCorp, 2007).
Box 1
MCADD of definite phenotype (genotype of
certain pathogenicity)
† persistent biochemical abnormality
AND
† c.985A . G homozygous
OR
† presence of two mutations, both either disease
associated or predicting truncated protein
MCADD of uncertain phenotype (genotype of
uncertain pathogenicity)
† persistent biochemical abnormality
AND
† two mutations, at least one of whose pathogen-
icity unknown
NB. phenotype determined by the ‘milder’ mutation
Carrier
† one mutation only (or with polymorphism)
AND
† trace or no persistent biochemical abnormality
Not MCADD
† no mutations
AND
† persistent biochemical abnormality but profile
not indicative of MCADD
OR
† no persistent biochemical abnormality
Independent Diagnostic Review Panel (DRP)
An independent expert panel was convened to agree case
definitions as a basis for assigning the outcome of screening
Figure 2 Diagnostic and clinical management schedule
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and determining its validity. Four categories were agreed as
shown in Box 1, with definite phenotype denoting clinically
important diagnoses that have a strong probability of severe
clinical presentation, and uncertain phenotype indicating
genotypes not previously encountered amongst clinically
presenting children or where a milder disease severity has
been reported.
The panel reviewed all screening and diagnostic results
and relevant clinical information for babies with presump-
tive positive screening results, independently of actual clini-
cal management, and assigned each to one of the four
categories as outlined in Figure 3. The panel’s final categor-
ization was not relayed to the paediatrician.
Ethics approval
The study was approved by the London Great Ormond Street
Hospital for Children NHS Trust Multi-centre Research Ethics
Committee (MREC) (Ref: 04/Q0508/2); and the Patient
Information Advisory Group (subsequently the Ethics and
Confidentiality Committee of the National Information
Governance Board) (Ref: PIAG/BPSU-2-10(e)/2005).
RESULTS
From March 2004 to February 2008, 1,568,445 babies (esti-
mated 79% white, 10% Asian, 5% black31) were screened
and 199 presumptive positive children referred; nine children
were inappropriately referred (C8 value lower than 0.5 mmol/
L). Of the remaining 190 babies, 90 were girls (48%, 1
missing), 157 (86%) were white, 16 (9%) were Asian, and
10 (5%) were from other (mixed/black/other) ethnic
groups (7 missing), giving an overall screen positive preva-
lence of 1.2 per 10,000 (95% CI 1.1–1.4). The estimated
screen positive prevalence amongst white and Asian babies
was 1.3 (95% CI 1.1–1.5) and 1.0 (95% CI 0.6–1.7) per
10,000, respectively. All subsequent results relate to the 190
infants referred according to the agreed protocol.
In 169 babies (89%, 1 missing), the screening sample was
taken between five to eight days with 13 (7%) taken before
day five and seven (4%) after day eight. Mean age at sample
analysis was 9.7 days (mode: 8 days; IQR: 8–11 days; 3
missing). Diagnostic blood samples were taken at a mean
age of 12 days (mode: 11 days; IQR 10–13 days; 5 missing).
The group assigned as ‘Not MCADD’ (n ¼ 14) included
five children with three other inborn errors of metabolism:
multiple acyl-CoA dehydrogenase deficiency (MADD) (n ¼
3), pyruvate dehydrogenase (PDH) deficiency (n ¼ 1) and
carbamoyl phosphate synthetase (CPS) deficiency (n ¼ 1),
and nine children classified as false-positive including
two premature infants (32 weeks gestation) both of whom
died with cardiac and respiratory problems. Babies in this
category were mostly identified by a full acylcarnitine scan
(Table 1).
The prevalence of disease detected through screening was
0.94 per 10,000 babies screened (147/1,568,445, 95% CI:
0.79–1.10), giving a positive predictive value (PPV) of 77%
overall (147/190, 95% CI: 71–83%), or 54% if only those
with MCADD of a definite phenotype are included (103/
190, 95% CI: 47–61%). Of those assigned as MCADD,
53% (78/147) were found to be homozygous for c.985A.G.
Figure 3 Diagnostic Review Panel (DRP) Decision Tree
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In babies of a definite clinical phenotype, 95% were white
and 2% were Asian ([95/100; 95% CI 89–98; 3 missing],
[2/100; 95% CI 0.1–7] respectively). For babies of uncertain
phenotype, 67% were white and 28% were Asian ([29/43;
95% CI 52–80; 1 missing], [12/43, 95% CI 16–43] respect-
ively). Seven of the 12 Asian babies were homozygous for
c.946-6T.G (IVS10-6T.G) in the 3’ splice site of exon 11
and one further Asian baby was heteroallelic for
c.985A.G/c.946-6T.G. Amongst white and Asian
infants, the overall PPV was 79% (124/157; 95% CI
72–85) and 88% (14/16; 95% CI 62–98) respectively. For
MCADD of a definite phenotype alone, the PPV amongst
white and Asian babies was 61% (95/157; 95% CI 53–68)
and 13% (2/16; 2–38) respectively, whereas for MCADD
of uncertain phenotype alone, the PPV was 18% (29/157;
95% CI 13–25) and 75% (12/16; 95% CI 48–93) for
white and Asian babies respectively.
Figure 4 shows screening and diagnostic C8 results for
individual babies by day of sample taken and DRP category.
Figure 5 shows diagnostic C8 and quantitative urine organic
acid results for individual babies by assigned DRP category.
The highest levels of C8 and quantitative UOA were
observed amongst those assigned as MCADD of definite
phenotype, particularly among those homozygous for
c.985A . G.
Test accuracy was found to be high at C8  0.5 mmol/L
with an area under ROC curve (Figure 6) of 0.904 compared
with 0.762 at C8  0.8 mmol/L (not shown). This reflected
the wide distribution of C8 screening results in babies con-
firmed as carriers and not MCADD.
Four babies were diagnosed before screening, of whom
one died at three days of age and three became clinically
unwell between days two and four. Furthermore, 12
babies with a previously diagnosed older sibling were
Table1 Biochemical results by DRP category (n ¼ 190)
Screening C8 mmol/L Diagnostic C8 mmol/L
Quantitative UOA
(hexanoylglycine)
mmol/mmol creatinine
Number (%)
Median (Interdecile
range)
Median (Interdecile
range)
Median (Interdecile
range)
MCADD – ALL 147 (77%) 1.63 (0.70–3.61) 1.36 (0.40–3.28)5 21.50 (5.40–37.00)12
MCADD – Definite phenotype 103 (54%) 1.88 (0.86–4.69) 1.72 (0.81–3.66)4 24.00 (13.40–40.00)7
c.985A . G homozygous 78 1.92 (0.86–4.69) 1.75 (0.99–3.75)3 24.10 (14.00–40.00)6
Other 25 1.81 (0.81–4.89) 1.40 (0.55–2.63)1 19.65 (7.50–40.00)1
MCADD – Uncertain phenotype 44 (23%) 0.87 (0.63–2.60) 0.86 (0.32–2.24)1 8.10 (1.50–26.90)5
Carrier 29 (15%) 0.62 (0.51–0.72) 0.23 (0.10–0.61)1 0.80 (0.40–2.00)3
Not MCADD 14 (7%) 0.72 (0.54–1.50) 0.25 (0.06–0.99)3 1.70 (0.40–48.40)4
Other conditions – MADD(3)
PDH(1), CPS(1) 5 0.62 (0.57–1.71) 0.57 (0.50–1.15)1 16.75 (0.50–65.70)1
False-positive 9 0.73 (0.51–1.50) 0.13 (0.03–0.99)2 0.90 (0.40–3.00)3
All screen positive 190 (100%) 1.16 (0.59–3.18) 1.14 (0.15–3.09)9 16.50 (0.80–34.70)19
SuperscriptN denotes number of missing observations
Figure 4 Screening and diagnostic C8 (mmol/L) by DRP category
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tested and diagnosed early. With the addition of these 16
diagnoses, the prevalence of MCADD is 1.0 per 10,000
(163/1,568,445). Five additional MCADD diagnoses were
made amongst older siblings in four families as a conse-
quence of a newly diagnosed screened infant, three of defi-
nite and two of uncertain phenotype. No reports of clinically
presenting (false-negative) MCADD cases were ascertained
within the first two years of life through concurrent
surveillance in this screened cohort.
DISCUSSION
We report findings from a large-scale prospective study
of newborn screening for MCADD conducted within a
multi-ethnic population where over 20% of the population
is non-white, principally Asian or black. This multicentre
collaboration across six centres used common protocols
for screening and diagnosis and developed a process by
which screen positive cases were independently reviewed
to assign MCADD diagnoses and infer their underlying
clinical severity.
Approximately 1 in 10,000 screened babies were diagnosed
with MCADD, approximately 60 per year in England. In the
majority, the biochemical and genetic features were consist-
ent with a high risk of clinical severity. The numbers of chil-
dren with false-positive or carrier diagnoses were minimal
reflecting prospective design features, namely thresholds
selected for referral as well as the decision to restrict genetic
testing to those referred. High specificity and overall PPV
were achieved – a key requirement of screening programmes,
demonstrating that the majority of babies who were detected
were likely to benefit from screening.
Babies who were assigned with a phenotype of definite
clinical importance were predominantly of white ethnic
origin, whereas nearly a third of those of uncertain pheno-
type were Asian. Whilst recognizing that the number of
Asian babies was small, these marked differences were
reflected in the estimated PPV for phenotypes of definite
and uncertain clinical importance amongst those of white
and Asian ethnicity. Of particular note were seven babies
homozygous for c.946-6T.G (IVS10-6T.G). In our study,
this mutation was only found amongst Asian babies and
has not previously been reported.
Particular strengths of this study include its large scale,
adherence to common protocols and high completeness of
data. In addition, we developed a novel classification
system allowing clinical severity to be inferred, and
Figure 6 ROC curve for C8 cut off 0.5 mmol/L
Figure 5 Diagnostic C8 (mmol/L) and quantitative UOA by DRP category
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appropriate for use within a screening programme in which
affected children are, in most cases, asymptomatic and/or
without family history. By categorizing babies this way, a
marker for measuring clinical validity of the screening pro-
gramme was established.
A limitation of our study is that clinical significance,
outcome and benefit for babies assigned as MCADD of
uncertain phenotype is not known, since almost all babies
identified through newborn screening are currently
treated, irrespective of the likely severity of their disease.
Thus, the natural history of novel mutations detected only
through screening remains difficult to assess. No false-
negative diagnoses were reported from this cohort over a
two-year follow-up, but longer-term follow-up is required.
We compare our data, as the largest such study published
worldwide, with recent, international studies which have
reported on the incidence, rate of MCADD diagnoses and
number of c.985A.G homozygotes detected through
newborn screening, summarized in Table 2, updating
recently published reports.2,12,48
Early neonatal presentation and death due to MCADD,
typically occurring around two to three days of age, has
been reported, but is uncommon and unlikely to be pre-
vented by newborn screening, given the timing of bloodspot
sample, analysis and reporting.7,9,18,49 In the UK, bloodspot
samples for newborn screening are taken between five to
eight days of age, later than in many countries.16,24,25,41
However, even within screening progammes which sample
blood earlier, typically between 48–72 hours, preventative
action would be unlikely as the screening result is reported
later. We therefore found no evidence in our study to
suggest that a change in UK screening policy to earlier
bloodspot sampling would prevent decompensation or
death in this early neonatal period.
The C8 cut-off set within England is lower than in many
countries which screen at an earlier age and we acknowl-
edge that the chosen cut-off must be appropriate for the
population in question and the age at which screening
takes place. We have recently examined C8 concentrations
in the first two weeks of life46 in an analysis of newborn
screening data for 227,098 infants from England and New
South Wales, Australia (average postnatal age at testing of
5 and 3 days respectively) in which we demonstrated that
median C8 concentrations do not vary significantly by age
of sampling in unaffected babies between day three and
day 14. Thus the cut-off in our study would be relevant to
samples collected over this age range.
MCADD dietary guidelines and other information for
parents and professionals, developed specifically through
this study, have worked well and are freely available for
parents and health-care professionals, along with current
UK Standards and Guidelines for Newborn Bloodspot
Screening from the UK Newborn Screening Programme
Centre, at www.newbornbloodspot.screening.nhs.uk.
For most babies, assignment of the diagnostic category
through the independent review process was straightfor-
ward. However, in a small number this proved difficult. In
two babies, both ultimately assigned as carriers, a second
mutation (in conjunction with c.985A.G) of unknown
clinical significance (c.387 þ 40G.A [or IVS5 þ 40G.A]
and c.388-9C.T [or IVS5-9C.T]) was identified but no bio-
chemical abnormality was detected at diagnosis, including
one with normal FAO studies. Furthermore, five babies,
also assigned as carriers (simple c.985A . G heterozygotes),
showed elevated diagnostic C8 (range 0.54–1.17 mmol/L)
despite having no second mutation identified at EMS and
no other biochemical abnormality detected including one
with normal FAO studies. These issues illustrate the difficul-
ties faced by paediatricians when deciding whether to treat a
child with borderline results or only some of the biomarkers
associated with MCADD. Whilst completely independent,
we are not aware of any discrepancies between assigned
classification and the final clinical management of the child.
Nine babies were inappropriately referred with an average
C8 result between 0.4 and 0.5 mmol/L. Diagnostic testing
revealed three carriers, four ‘Not MCADD’ and two assigned
as MCADD of uncertain phenotype. Of the latter two, one
had no biochemical abnormalities detected at diagnostic
testing and was found to be heteroallelic for c.985A.G and
c.127G.A. Previous studies note that this genotype does not
express the biomarkers normally associated with
MCADD.5,40,41,43 The second case was found to be heteroallelic
for c.985A.G and c.199T.C, and, although both C8 results
fell below the 0.5 mmol/L cut-off, some organic acid abnorm-
alities were detected. We acknowledge that by strict adherence
to an agreed C8 cut off, there may occasionally be cases of
(mild) MCADD which are not detected through screening.
However, screening is not diagnosis and, by reviewing and
reporting these findings, we are able to conclude that at least
seven of these nine referrals were made unnecessarily.
Very few carriers were detected in relation to expected total
carrier pool. Carrier frequency for c.985A.G in the white UK
population has been estimated at 1/65 (95% CI 1/71–1/
61)31 assuming Hardy Weinberg equilibrium. Within our
screened study population (n ¼ 1,568,445), an estimated
79.5% or 1,246,914 were white, of which 19,183 (or 1.5%)
would be anticipated c.985A.G carriers.31 In total, 23
white, c.985A.G heterozygote carriers were detected over
the four-year study, 0.1% of the expected frequency.
Moreover, we expect that the number of carriers identified
Table 2 Estimated incidence of MCADD through newborn screening
Area No. Screened No. MCADD
Incidence
(per 100,000) Rate
No. c.985A . G HMZ
(% of all MCADD)
England (pilot screening study) 1,568,445 147 9.4 1/10,700 78 (53%)
Canada (Ontario)48 439,000 31 7.1 1/14,000 15 (48%)
Australia (NSW)16 461,500 24 5.2 1/19,200 12 (50%)
USA (NY State)26 385,893 20 5.2 1/19,300 6 (30%)
Germany (Bavaria)25 470,247 58 12.3 1/8,100 24 (41%)
Netherlands24 66,216 14 21.1 1/6,600 10 (71%)
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through newborn screening for MCADD to be further
reduced, as of April 2010, by the introduction within the
screening protocol of an additional C8/C10 ratio measure-
ment with a referral cut off 1.0. Use of the C8:C10 ratio
has been shown to discriminate between MCADD pheno-
types well.41,50–52 Screen positive MCADD referrals in
England will now only be made if C8  0.5 mmol/L and
C8/C10  1.0. We have estimated through a specific research
audit within this study (results not presented here), that the
detection of carriers and those assigned as ‘Not MCADD’
will be reduced by over 90%, minimizing unnecessary refer-
ral and anxiety for families and increasing the predicted PPV
at screening for all MCADD phenotypes to over 95%.
Our findings demonstrate that prospectively defined,
quality assured screening and diagnostic protocols allow
identification of children with clinically important disease
whilst minimizing the harms of screening related to the
detection of children with biochemical or genetic variations
of uncertain prognostic significance.
In 2006, interim data from this study were reviewed by
the UK National Screening Committee and, as a result,
MCADD screening was successfully implemented across
England by April 2009.
CONCLUSION
Newborn screening identifies MCADD in 1/10,000 babies
born in England. In the majority, the features indicate a
phenotype of definite clinical importance, suggesting that
the validity of newborn screening is high. Ethnic variations
in genotype and phenotype were noted. Diagnostic protocols
need to reflect the ethnic diversity of the contemporary
English population. This prospective collaborative study sup-
plied evidence and informed the policies for a high-quality
and rapidly implemented screening programme, and
further enhances the information available for evaluating
newborn screening for rare disorders in multi-ethnic
populations.
Abbreviations: MCADD – Medium chain acyl-CoA
dehydrogenase deficiency; DRP – Diagnostic Review Panel;
EMS – Extended Mutation Screening; FAO – Fatty acid oxi-
dation; ER – Emergency regimen; DBS – Dried blood spot;
UOA – Urine organic acid; C8 – Octanoylcarnitine; PPV –
Positive predictive value; EQA – External quality assurance;
MS/MS – Tandem mass spectrometry
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